Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. (URGN) – Form 144 filing. An unidentified insider has notified the SEC of an intended open-market sale of 7,522 ordinary shares through Oppenheimer & Co. on or after 28 Jul 2025. Based on the filer’s estimate, the block is worth $142,541.90, implying an indicative price of roughly $18.95 per share. The shares represent 0.016% of the company’s 46.1 million shares outstanding, a small fraction of float but still a required disclosure under Rule 144.
The shares stem from 16,500 restricted stock units granted and vested on 31 Jan 2024. The filer reports no other URGN share sales in the prior three months. The filer also certifies that no undisclosed material adverse information is known. While modest in size, the transaction flags upcoming insider liquidity and may be watched as a sentiment signal.